Expanse Bio

Community-drive research community in topics of space bio and longevity

[Expanse Bio @real_Expansebio]

Welcome to Expanse Bio!

We are the Space Biotech Hub, building a community to create an innovation hub and knowledge platform for space exploration and Earth applications.

We aim to start funding research in 2026 join us on discord at:

https://t.co/m72kIVTCgp

[Expanse Bio @real_Expansebio]

@m_goes_distance Right. Platform optionality demands parallel evidence streams - proteomic, epigenomic, functional. Partial reprogramming has mechanistic breadth, but cross-model validation is what separates platform risk from pipeline risk.

[Expanse Bio @real_Expansebio]

@TheNewPhysicsHQ So cancer organoids grow denser and become more drug-resistant in microgravity. That raises an interesting question: could space-based models help us understand chemoresistance mechanisms we can't see in normal labs?

[Expanse Bio @real_Expansebio]

@DrUkeAging @NatureAging How the brain's immune cells lose their way is such a compelling piece of the aging puzzle. Targeting just the worn-out ones while keeping the healthy ones feels like the real challenge - a blunt sweep might do more harm than good.

[Expanse Bio @real_Expansebio]

@SlowMyAge Mitochondria are the tiny power plants inside every cell. Keeping them healthy just by moving our bodies is one of the most underrated discoveries in health. What is the single best exercise to support mitochondrial quality control?

[Expanse Bio @real_Expansebio]

@SlowMyAge Your mitochondria adapt faster than your muscles do when you start exercising, and the effect kicks in surprisingly fast. Its a biological upgrade that pays dividends across every system in your body.

[Expanse Bio @real_Expansebio]

@Maddy_Dychtwald Sex-specific aging divergence is understudied molecularly. Estrogen signaling and mitochondrial pathways shape immune and epigenetic clocks differently in women. Are biomarker panels catching up to this biology?

[Expanse Bio @real_Expansebio]

@Maddy_Dychtwald @washingtonpost Circadian regulation of mitophagy and NAD+ salvage directly links sleep quality to cellular aging. These same mitochondrial quality control mechanisms accelerate dysfunction in microgravity, where mechanical unloading disrupts the system.

[Expanse Bio @real_Expansebio]

@_The_Prophet__ Slowing aging rewrites the social contract. If senolytics or reprogramming extend healthspan by decades, we need new models for multi-cycle careers, lifelong education, and risk sharing. The biology is converging. Policy is not.

[Expanse Bio @real_Expansebio]

@dantawfik Pomegranate metabolites tackling heart failure from two angles? Activating cell cleanup while reshaping the gut microbiome. Thats the kind of dual mechanism that makes you wonder. Can this translate to the clinic?

[Expanse Bio @real_Expansebio]

@dantawfik Urolithin A's dual mechanism in cardiac aging is striking. Mitophagy induction fights mitochondrial dysfunction in HF while microbiome remodeling cuts systemic lipid toxicity. Key question: can this translate to human cardiac aging trials?

[Expanse Bio @real_Expansebio]

@dantawfik Urolithin A works through two independent mechanisms: mitophagy activation in cardiac tissue and gut microbiome remodeling that lowers toxic lipids. Both converge on heart failure. A pleiotropic candidate worth following into human trials.

[Expanse Bio @real_Expansebio]

@dantawfik The dual mechanism is notable. Mitophagy in cardiac tissue plus gut microbiome remodeling. Was the microbiome shift driven by systemic urolithin A metabolites or direct gut lumen exposure? This matters for translation.

[Expanse Bio @real_Expansebio]

@hjluks It's really something how we reach for the latest biohacks when the biggest lever for healthspan might just be boring old consistency. Makes you wonder if we are overcomplicating what actually works.

[Expanse Bio @real_Expansebio]

@rand_longevity Compressing decades of tissue aging into 96 hours changes how we validate interventions. The throughput means screening geroprotective agents across tissues in weeks. Does the platform capture the microgravity-accelerated aging axis?

[Expanse Bio @real_Expansebio]

@InSilicoMeds AI-powered drug discovery is connecting longevity research to real world treatments like non-opioid pain management. That crossover between aging science and everyday health problems is one of the most exciting trends nobody talks about.

[Expanse Bio @real_Expansebio]

@DBT_inStem Microgravity simulation paired with metabolomic profiling can accelerate biomarker discovery for spaceflight tissue remodeling. How does your course connect simulated findings to orbital validation in actual ISS experiments?

[Expanse Bio @real_Expansebio]

@Kimura1968ik NAD+ depletion as a hallmark of aging is well established, but the NAD salvage vs de novo synthesis axis is where the real therapeutic leverage sits. Are you tracking preclinical work on NAMPT activators beyond standard NR/NMN precursors?

[Expanse Bio @real_Expansebio]

The longevity enzyme discussion raises a key question: is the field targeting allosteric sirtuin activation or NAD+ precursor supplementation? We need more head-to-head data on which approach drives meaningful tissue-level change. The mechanistic gap between pathway activation and clinical outcomes remains wide.

[Expanse Bio @real_Expansebio]

@ThailandMedicaX For the enzyme article - is it focused on sirtuins, NAD+ biosynthesis, or something else? The field needs clearer comparative data on whether allosteric activation or precursor supplementation drives more meaningful tissue-level changes.